Clinical Trials
192 trialsPartial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
GAIN-BCG
Alliance for Clinical Trials in Oncology
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
First Affiliated Hospital of Fujian Medical University
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Noninvasive Urine Testing for Urothelial Carcinoma
Henan Provincial People's Hospital
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
LORUP
Umeå University
DK222 Study at Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
RABBIT
University of Arizona
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
University Hospital, Basel, Switzerland
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
Lanzhou University Second Hospital
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
BCG at Home
Abramson Cancer Center at Penn Medicine
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
RECIPE-B1
Mayo Clinic
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
Rutgers, The State University of New Jersey
DISCUS
Queen Mary University of London
iCaRe2
University of Nebraska
SR-ULM BC
Duke University
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Bladder Cancer Screening Trial
University of Texas Southwestern Medical Center
TVNIM-AFU
Association Francaise d'Urologie
ASTRA
Istituto Clinico Humanitas
CER
Cancer Support Community, Research and Training Institute, Philadelphia
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CISTO2
University of Washington
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Measuring Surgical Recovery After Radical Cystectomy
M.D. Anderson Cancer Center
ADAPT-BLADDER
Hoosier Cancer Research Network
Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
DutaBCa-1
CHU de Quebec-Universite Laval
PRO-GAG
BLAD-HYA Group
(CLOCS-2)
Imperial College London
METRICS
University of Kansas Medical Center
MicroBlad
University Hospital, Toulouse
Bladder Bank (a Prospective Banking Study)
Mayo Clinic
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
University of California, Davis
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
EMPOWER
University of Washington
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
GUB-BCR-001
University of Kansas Medical Center